10月9日，康希诺生物盘中下跌5.34%，报34.02港元，成交额3311.58万港元。
消息面上，隔夜美股疫苗巨头莫德纳暴跌，加上花旗将莫德纳评级下调至卖出，负面情绪跨市场传导至港股疫苗及创新药板块。此前受ESMO年会数据预期提振，康希诺生物在国庆期间连续大涨，累计涨幅较大，短期获利盘回吐压力显著。公司与德普世生物合作的mRNA个性化肿瘤疫苗仍处于早期开发阶段，市场对短期估值兑现趋于谨慎。
康希诺生物股份公司是一家处于临床阶段的中国疫苗公司，产品主要应用于脑膜炎、百白破和肺炎领域，业务涵盖创新疫苗研发、生产及商业化。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.